A phase I trial employing a combination of cixutumumab (anti-IGF1R antibody) and selumetinib (MEK 1⁄2 inhibitor) obtained promising results offering the evidence of the health benefit and target inhibition in a cohort of 30 patients, including those with CRC [209]. This evidence concerns the gene IGF1R and colorectal carcinoma.